Janus Henderson Group PLC Has $488.70 Million Holdings in Zoetis Inc. $ZTS

Posted by Sarita Garza on Jun 18th, 2026

Janus Henderson Group PLC lifted its position in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 69.6% during the 4th quarter, Holdings Channel.com reports. The firm owned 3,884,112 shares of the company’s stock after purchasing an additional 1,593,375 shares during the quarter. Janus Henderson Group PLC’s holdings in Zoetis were worth $488,698,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Global Wealth Strategies & Associates acquired a new stake in shares of Zoetis during the 4th quarter worth approximately $25,000. Prosperity Bancshares Inc acquired a new stake in shares of Zoetis during the 4th quarter worth approximately $25,000. KERR FINANCIAL PLANNING Corp acquired a new stake in shares of Zoetis during the 3rd quarter worth approximately $31,000. Lodestone Wealth Management LLC acquired a new stake in shares of Zoetis during the 4th quarter worth approximately $30,000. Finally, Elyxium Wealth LLC acquired a new stake in shares of Zoetis during the 4th quarter worth approximately $32,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Price Performance

Shares of ZTS stock opened at $77.26 on Thursday. The stock’s fifty day simple moving average is $94.59 and its 200 day simple moving average is $113.13. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. The firm has a market cap of $32.39 billion, a price-to-earnings ratio of 12.81, a P/E/G ratio of 1.24 and a beta of 0.75. Zoetis Inc. has a one year low of $72.38 and a one year high of $161.77.

Zoetis (NYSE:ZTS – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing the consensus estimate of $1.60 by ($0.07). The company had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. Zoetis’s quarterly revenue was up 2.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, analysts expect that Zoetis Inc. will post 6.88 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be paid a $0.53 dividend. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 annualized dividend and a yield of 2.7%. Zoetis’s payout ratio is currently 35.16%.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on ZTS shares. Stifel Nicolaus decreased their price objective on Zoetis from $105.00 to $95.00 and set a “hold” rating on the stock in a report on Friday, May 22nd. Weiss Ratings lowered Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, June 12th. Wall Street Zen lowered Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Leerink Partners reissued a “market perform” rating on shares of Zoetis in a report on Tuesday, March 10th. Finally, Citigroup decreased their price objective on Zoetis from $145.00 to $112.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Six equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $133.92.

Read Our Latest Stock Report on Zoetis

Key Zoetis News

Here are the key news stories impacting Zoetis this week:

Negative Sentiment: Multiple law firms, including Rosen, Bronstein, Gewirtz & Grossman, Kessler Topaz Meltzer & Check, Levi & Korsinsky, Bernstein Liebhard, Pomerantz, and The Gross Law Firm, announced or promoted a securities fraud class action against Zoetis covering purchases from January 14, 2025 through May 6, 2026. Article: Rosen, A Leading Law Firm, Encourages Zoetis Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ZTS
Negative Sentiment: The lawsuits appear to center on alleged misleading statements about companion animal product performance, along with safety concerns and competitive losses, which could raise legal costs and create headline risk for Zoetis. Article: ZTS Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Zoetis Inc. Securities Lawsuit – Contact Levi & Korsinsky
Neutral Sentiment: Several notices highlight a July 27, 2026 lead plaintiff deadline, which is mainly procedural but reinforces the ongoing litigation overhang on the stock. Article: Zoetis Inc. (ZTS) Investors: July 27, 2026, Deadline in Securities Fraud Class Action Lawsuit – Contact Kessler Topaz Meltzer & Check, LLP

Insider Activity at Zoetis

In related news, Director Frank A. Damelio purchased 6,650 shares of the firm’s stock in a transaction that occurred on Wednesday, May 13th. The shares were acquired at an average price of $75.39 per share, with a total value of $501,343.50. Following the purchase, the director directly owned 21,458 shares in the company, valued at $1,617,718.62. This represents a 44.91% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Michael B. Mccallister purchased 3,000 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was bought at an average cost of $77.76 per share, for a total transaction of $233,280.00. Following the purchase, the director owned 24,524 shares in the company, valued at $1,906,986.24. This represents a 13.94% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 11,650 shares of company stock valued at $886,384 in the last 90 days. 0.22% of the stock is owned by corporate insiders.

Zoetis Profile

(Free Report)

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.